Market research
ATX.AU Amplia Therapeutics Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 41M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- Not available
- Beta
- -0.33
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000023822
- Market cap
- 41M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- Not available
- Beta
- -0.33
About
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Research context
Amplia Therapeutics Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ATX.AU discussion.
5 years, 7 months ago
Amplia Therapeutics Limited is currently in a long term downtrend where the price is trading 7.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Amplia Therapeutics Limited's total revenue rose by 2426.2% to $34K since the same quarter in the previous year.
Its net income has increased by 42.3% to $-511K since the same quarter in the previous year.
Finally, its free cash flow grew by 57.9% to $-469K since the same quarter in the previous year.
Based on the above factors, Amplia Therapeutics Limited gets an overall score of 4/5.